Unfortunately, Big Government getting it wrong on food, nutrition, and health did not begin with COVID-19 or even the ...

Semaglutide, the scientific name for Novo’s GLP-1 diabetes drug Ozempic and obesity drug Wegovy, has been on the shortage ...

Danish pharmaceutical giant Novo Nordisk sees a significant increase in profits and sales despite production constraints.

In good news for those averse to injections, GLP-1 agonist medication is a step closer to being offered in oral pill form, ...

LONDON — Novo Nordisk said on Wednesday it was aware of reports of 10 deaths and 100 hospitalizations of people who had taken compounded copies of its weight-loss and diabetes drugs. U.S ...

Novo Nordisk’s blockbuster Wegovy weight-loss drug beat sales expectations in the third quarter, sending shares 8.5% higher in early trade. Soaring popularity for its obesity drug has seen ...

Ascendis Pharma and Novo Nordisk announced a partnership to develop cardiovascular ... BioNTech lowered its guidance for full ...

Novo Nordisk's blockbuster drugs Ozempic and Wegovy have slimmed down Hollywood stars and millions of non-celebrities worldwide — all while adding great heft to Denmark's economy. Novo Nordisk ...

Novo Nordisk (NVO) reported mixed earnings for the third quarter of 2024 but beat Wall Street revenue expectations for its blockbuster weight-loss drug, Wegovy. Novo announced an earnings per ...

In a deal worth up to $285 million initially for the lead program, Novo Nordisk will gain access to Ascendis’ TransCon ...

COPENHAGEN (Reuters) - Novo Nordisk is lifting curbs on prescriptions of its weight-loss drug Wegovy in the United States and is increasing supply in that market, its CEO said on Wednesday.